JP2002524492A5 - - Google Patents

Download PDF

Info

Publication number
JP2002524492A5
JP2002524492A5 JP2000569779A JP2000569779A JP2002524492A5 JP 2002524492 A5 JP2002524492 A5 JP 2002524492A5 JP 2000569779 A JP2000569779 A JP 2000569779A JP 2000569779 A JP2000569779 A JP 2000569779A JP 2002524492 A5 JP2002524492 A5 JP 2002524492A5
Authority
JP
Japan
Prior art keywords
composition
active substance
composition according
therapeutically
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000569779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524492A (ja
JP5026635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK1999/000480 external-priority patent/WO2000015195A1/en
Publication of JP2002524492A publication Critical patent/JP2002524492A/ja
Publication of JP2002524492A5 publication Critical patent/JP2002524492A5/ja
Application granted granted Critical
Publication of JP5026635B2 publication Critical patent/JP5026635B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000569779A 1998-09-10 1999-09-10 医薬物質の迅速放出医薬組成物 Expired - Lifetime JP5026635B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801143 1998-09-10
DK199801143 1998-09-10
DKPA199801143 1998-09-10
PCT/DK1999/000480 WO2000015195A1 (en) 1998-09-10 1999-09-10 Quick release pharmaceutical compositions of drug substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011227314A Division JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Publications (3)

Publication Number Publication Date
JP2002524492A JP2002524492A (ja) 2002-08-06
JP2002524492A5 true JP2002524492A5 (https=) 2006-11-24
JP5026635B2 JP5026635B2 (ja) 2012-09-12

Family

ID=8101500

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000569779A Expired - Lifetime JP5026635B2 (ja) 1998-09-10 1999-09-10 医薬物質の迅速放出医薬組成物
JP2011227314A Expired - Lifetime JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011227314A Expired - Lifetime JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Country Status (13)

Country Link
US (1) US6713089B1 (https=)
EP (1) EP1109534B1 (https=)
JP (2) JP5026635B2 (https=)
AT (1) ATE232382T1 (https=)
AU (1) AU5504599A (https=)
CA (1) CA2343148C (https=)
DE (1) DE69905380T2 (https=)
DK (1) DK1109534T3 (https=)
EA (1) EA004032B1 (https=)
ES (1) ES2190241T3 (https=)
PT (1) PT1109534E (https=)
TR (1) TR200100708T2 (https=)
WO (1) WO2000015195A1 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GEP20094671B (en) * 2004-06-29 2009-04-27 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
JP5490347B2 (ja) * 2005-05-27 2014-05-14 エスエス製薬株式会社 経口投与用製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
CA2614850A1 (en) 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2661818A1 (en) * 2006-05-03 2007-11-15 Kowa Pharmaceuticals America, Inc. Acute pain medications based on fast acting diclofenac-opioid combinations
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008062449A2 (en) * 2006-09-18 2008-05-29 Glenmark Pharmaceuticals Limited A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
EP3070090B1 (en) * 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
PL2240018T3 (pl) * 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
RU2010151953A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Карбонатные продукты и способы их применения
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
MX389960B (es) 2009-10-12 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Recipientes para composiciones que comprenden meloxicam.
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012146314A1 (en) 2011-04-29 2012-11-01 Refarmed Chemicals Sa Thin gelatin capsules for rapid drug release in the mouth
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP2012012411A (ja) * 2011-10-03 2012-01-19 Ssp Co Ltd 経口投与用製剤
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
JP2013216701A (ja) * 2013-07-29 2013-10-24 Ssp Co Ltd 経口投与用製剤
KR101890649B1 (ko) * 2013-07-30 2018-09-28 라이온 가부시키가이샤 정제
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
PT3164117T (pt) 2014-07-03 2023-12-12 SpecGx LLC Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
UA126916C2 (uk) 2017-04-27 2023-02-22 Др. Редді'З Лабораторіз Лімітед Фармацевтична композиція кеторолаку
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
JP7170437B2 (ja) * 2018-06-29 2022-11-14 小林製薬株式会社 内服用医薬組成物
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
JP7499025B2 (ja) * 2019-12-27 2024-06-13 小林製薬株式会社 内服用医薬組成物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
EP4181912A1 (en) 2020-07-15 2023-05-24 Schabar Research Associates LLC Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2002524492A5 (https=)
AU712464B2 (en) Improvements in or relating to organic compositions
CZ20011029A3 (cs) Farmaceutický přípravek pro ošetření akutních potíží
JP5161071B2 (ja) 胃酸分泌
PT1341528E (pt) Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
CN101626755B (zh) 包含酸不稳定药物的双单元片剂
JP7482182B2 (ja) プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法
EA014443B1 (ru) Фармацевтическая композиция (варианты) и способ ее производства
KR20070083956A (ko) 양성자 펌프 억제제를 위한 신규 변형 방출 정제 제형
JP4276545B2 (ja) 改良組成物
TW202227066A (zh) 為錠劑形式之含奧美拉唑、埃索美拉唑或其醫藥上可接受鹽之醫藥組成物及其製備程序
TW200307564A (en) New pharmaceutical composition
CA2616543A1 (en) Particulate compositions comprising alginate and/or alginic acid
JP2014240435A (ja) 胃酸分泌を阻害するための組成物および方法
RU2007120753A (ru) Порошкообразная антацидная фармацевтическая композиция, содержащий ее фармацевтический препарат и способ ее получения
TW201035089A (en) Pharmaceutical composition
WO2011080502A2 (en) New pharmaceutical dosage form for the treatment of gastric acid-related disorders
JP2017119655A (ja) 炭酸ランタンを含む口腔内崩壊錠
WO2010001930A1 (ja) 固形内服製剤
EP1684728B1 (en) Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate
EA014187B1 (ru) Таблетка, содержащая гранулированный пантопразол
CN101500553B (zh) 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
AU2006341307B2 (en) Particulate compositions comprising alginate and/or alginic acid
WO2025171802A1 (zh) 雷贝拉唑药物组合物、其制备方法及应用
JP2013006843A (ja) 胃酸分泌